A New Tool to Accurately Diagnose Type 1 in Adults
Misdiagnosing adults with type 1 diabetes (T1D) is an all-too-common problem that can have tragic consequences. Breakthrough T1D and IQVIA partnered up to tackle it—and the results were just published.
Breakthrough T1D Urges Senate to Support Insulin Affordability Provisions as Part of Inflation Reduction Act of 2022
Breakthrough T1D Urges Senate to Support Insulin Affordability Provisions as Part of Inflation Reduction Act of 2022
Diabetes Research in Pediatrics? The International Society Has Your Back
Learn more about the recipients of the International Society for Pediatrics and Adolescent Diabetes (ISPAD)-Breakthrough T1D Fellowships here!
California to Manufacture Insulin
California Governor Gavin Newsome announced plans for the state to manufacture and distribute its own insulin.
Breakthrough T1D welcomes new Chair and members to Global Mission Board
Longtime volunteer Jennifer Bennett has been appointed Chair of the Breakthrough T1D Global Mission Board, effective July 1, 2022.
Remembering T1D Champion Steve Davis
Steve Davis was a leader in the restaurant and consumer packaged goods industries, but to Breakthrough T1D, he was a beloved member of the family.
Breakthrough T1D Timeline: Stem Cell Therapies
Stem cells have the potential to lead to treatments for type 1 diabetes, but it has taken Breakthrough T1D more than 20 years to get to this point.
At ADA, Breakthrough T1D-Funded Research Takes Center Stage (with a “Happy Hour” by Dr. Aaron Kowalski)
At the ADA’s Scientific Sessions, Breakthrough T1D scientists presented on some of the most important topics, all with the same goal: Ending type 1 diabetes.
Breakthrough T1D Heads—In Person!—to ADA’s 82nd Scientific Sessions
From June 3-7, diabetes researchers around the world will gather—in person!—at the American Diabetes Association’s 82nd Scientific Sessions. #JDRFxADA
FDA Approved! Abbott FreeStyle Libre® 3 Continuous Glucose Monitor, Ages 4+
The FDA cleared the FreeStyle Libre 3 continuous glucose monitor (CGM) for children and adults ages 4 and up with diabetes
